Entourage Health Reports 2021 Preliminary Data, Q4 Revenues Appear To Slip
Entourage Health (TSXV: ENTG) this morning provided preliminary revenue figures for the full fiscal year of 2021. The company reportedly on a preliminary basis recorded total revenues of $54.8 million for the twelve month period.
The preliminary revenue figure represents a large improvement over 2020, which saw total revenues of $35.5 million, and net revenues of $29.4 million.
However, with the firm reporting year to date total revenues of $41.7 million as of September 30, it indicates that revenue declined on a total basis, while on a net basis its less certain when it comes to the fourth quarter. On a quarterly basis, total revenues are expected to come in at $13.1 million, versus the $15.0 million figure recorded in the third quarter, a 12.7% decrease.
Full financial results for the fourth quarter are slated to be released by April 1, 2022.
The company this morning also announced that interim CEO George Scorsis has now been named to the role on a permanent basis. Scorsis has served in the role since January 2021, while also serving as executive chair since December 2019.
Entourage Health last traded at $0.10 on the TSX Venture.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
